3 Reasons You Might Hate Being a Medicare Enrollee in 2026

Medicare costs rise in 2026 with the standard Part B premium increasing from $185 in 2025 to $202.90 in 2026, the Part A inpatient deductible rising from $1,676 to $1,736, Part A coinsurance for days 61–90 up from $419 to $434 per day, and lifetime reserve day costs rising from $838 to $868 per day. These changes effectively reduce disposable income for beneficiaries—eroding much of a 2.8% Social Security COLA—and signal continued upside pressure on healthcare-related consumer costs, a modest macro headwind for older household spending and fiscal pressures on entitlement programs.

Analysis

Market structure: A ~9.7% jump in Part B premiums (from $185 to $202.90) plus ~3.6% lifts in Part A deductible/coinsurance forces retirees to shift spend from discretionary goods to health insurance and supplemental coverage. Direct winners are Medicare Advantage and Medigap writers (scale, underwriting, network control) while elective-care-heavy hospitals and outpatient elective providers face demand headwinds; pricing power shifts toward payors that can manage utilization and capture supplemental premiums.

Risk assessment: Near-term (weeks) risk is muted but hinges on CMS rate guidance and fall open-enrollment cues; medium-term (3–12 months) risks include regulatory pushback if premiums rise >5–10% year-over-year and a recession that amplifies utilization drops. Tail risks include swift legislative intervention or a court finding that forces coverage/price adjustments; hidden dependencies include interaction with Social Security COLA erosion and retirees drawing down equities to pay higher premiums.

Trade implications: Favor insurers with MA footprints and PBM integration (UNH, HUM, CVS) and underweight/short elective hospital operators (HCA, THC) where >3–6 month demand elasticity can compress margins. Use relative-value pair trades (long UNH vs short HCA) and option structures to cap downside while keeping upside exposure around key catalysts (CMS rate announcements, Oct open enrollment).

Contrarian angles: The market may underprice durable demand for Medigap and supplemental products — underwriting margin tailwinds if insurers reprice effectively — while overpricing hospital catastrophe from these increases. Historical parallels (post-ACA MA share gains) suggest payors can translate enrollment momentum into outsized profit growth over 12–24 months if regulatory shocks don’t materialize.

Key Decisions for Investors

• Establish a 2–3% long position in UnitedHealth (UNH) within 2–6 weeks, target 10–15% total return over 12 months driven by MA enrollment and PBM leverage; set a stop loss at -8% and trim if UNH outperforms peers by >7% relative in 3 months.
• Add a 1–2% long position in Humana (HUM) as a focused Medicare Advantage play to benefit from supplemental/Medigap demand; use a 6-month call-spread (buy ATM, sell +12% OTM) to limit premium spend if implied volatility >20%.
• Implement a dollar-neutral pair trade: long UNH vs short HCA Healthcare (HCA) equal notional (1–2% portfolio each) to capture payor vs provider dispersion; hedge with a 3-month HCA bear-put spread (buy 10% OTM put, sell 6% OTM put) sized to cap max loss to ~2% of portfolio.
• Monitor CMS announcements and Oct 2026 MA enrollment guidance over the next 30–90 days: if MA rate increases exceed 3% sequentially or CMS signals benefit expansion, reduce hospital shorts by 50% and rotate proceeds into insurers; if legislative hearings on premium hikes are scheduled within 60 days, tighten stop losses on insurer longs by 25%.